Research Highlights

Treatment with teclistamab, a bispecific antibody, was recently approved for patients with relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study results. However, while multiple myeloma primarily affects the elderly, only 15% of patients in the Phase I/II trial were aged 75 or older, highlighting a need to evaluate teclistamab’s safety and efficacy in older patients. Therefore, researchers led by Oren Pasvolsky, M.D...

Lung cancer is often diagnosed at late stages, making treatment challenging. To understand its early development, researchers led by Bo Zhu, Ph.D., Jia Wu, Ph.D., Alexandre Reuben, Ph.D., and Jianjun Zhang, M.D., Ph.D., used imaging mass cytometry to map the spatial tumor microenvironment across 114 lung cancers and precancers. They found a gradual shift from innate to adaptive immune responses as lesions progressed to...